Trial
NCT04951492
Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Washington
Collaborators
AstraZeneca
Condition
Castration-Resistant Prostate Carcinoma
Intervention
Olaparib
Why stopped
Withdrawal of funding
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-01-01